Payment overview · 2025
General Payments
$129.43
5 reported records · 4 companies
Healthcare provider profile · identity verified
Vincent B. Barker, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · BLAKELY, GA · NPI 1821039660
Verified facts
What the public records show
CMS Open Payments records show Vincent B. Barker, M.D. received $129.43 in general payments during 2025 across 5 reported records.
Lilly USA, LLC accounted for 34.8% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 3 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Symbicort by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.00 | 34.8% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $42.66 | 33.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $23.08 | 17.8% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $18.69 | 14.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $84.43 | 4 |
| Education | $45.00 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $42.66 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $23.08 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $18.69 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 488 | 105 |
| Amlodipine Besylate | Amlodipine Besylate | 382 | 94 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 304 | 77 |
| Sertraline Hcl | Sertraline Hcl | 235 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 222 | 61 |
| Potassium Chloride | Potassium Chloride | 216 | 59 |
| Levothyroxine Sodium | Levothyroxine Sodium | 215 | 59 |
| Gabapentin | Gabapentin | 208 | 56 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 46 |
| Lisinopril | Lisinopril | 174 | 45 |
| Furosemide | Furosemide | 173 | 50 |
| Eliquis | Apixaban | 171 | 32 |
| Metformin Hcl | Metformin Hcl | 169 | 34 |
| Metoprolol Tartrate | Metoprolol Tartrate | 163 | 45 |
| Losartan Potassium | Losartan Potassium | 160 | 43 |
| Donepezil Hcl | Donepezil Hcl | 139 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 138 | 26 |
| Carvedilol | Carvedilol | 134 | 27 |
| Trazodone Hcl | Trazodone Hcl | 128 | 36 |
| Famotidine | Famotidine | 126 | 26 |
| Omeprazole | Omeprazole | 124 | 37 |
| Quetiapine Fumarate | Quetiapine Fumarate | 121 | 16 |
| Metoprolol Succinate | Metoprolol Succinate | 116 | 25 |
| Simvastatin | Simvastatin | 110 | 28 |
| Levetiracetam | Levetiracetam | 109 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 34 |
| Allopurinol | Allopurinol | 103 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 101 | 22 |
| Tramadol Hcl | Tramadol Hcl | 87 | 36 |
| Nifedipine Er | Nifedipine | 86 | 22 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 82 | 27 |
| Valsartan | Valsartan | 79 | 16 |
| Memantine Hcl | Memantine Hcl | 75 | 18 |
| Montelukast Sodium | Montelukast Sodium | 71 | 24 |
| Entresto | Sacubitril/Valsartan | 59 | 13 |
| Meloxicam | Meloxicam | 58 | 25 |
| Prednisone | Prednisone | 58 | 49 |
| Bumetanide | Bumetanide | 55 | 16 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 54 | 51 |
| Buspirone Hcl | Buspirone Hcl | 54 | 11 |
| Alprazolam | Alprazolam | 52 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 46 | suppressed |
| Mirtazapine | Mirtazapine | 46 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 45 | 41 |
| Fenofibrate | Fenofibrate Nanocrystallized | 45 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 43 | 13 |
| Metoclopramide Hcl | Metoclopramide Hcl | 43 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 42 | 14 |
| Clonazepam | Clonazepam | 41 | 13 |
| Dexamethasone | Dexamethasone | 41 | 40 |
| Xarelto | Rivaroxaban | 40 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 40 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 39 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 39 | suppressed |
| Lorazepam | Lorazepam | 39 | 13 |
| Methylprednisolone | Methylprednisolone | 39 | 37 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 39 | suppressed |
| Atenolol | Atenolol | 38 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 38 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Pregabalin | Pregabalin | 36 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 36 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 35 | 27 |
| Levofloxacin | Levofloxacin | 35 | 29 |
| Fluticasone Propionate | Fluticasone Propionate | 34 | 17 |
| Risperidone | Risperidone | 34 | suppressed |
| Azithromycin | Azithromycin | 32 | 31 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 32 | 30 |
| Duloxetine Hcl | Duloxetine Hcl | 29 | suppressed |
| Glipizide Er | Glipizide | 29 | suppressed |
| Linzess | Linaclotide | 29 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 29 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 28 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 28 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 28 | 13 |
| Ondansetron Odt | Ondansetron | 28 | 22 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 28 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 28 | suppressed |
| Sucralfate | Sucralfate | 28 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 27 | 23 |
| Fluconazole | Fluconazole | 27 | 25 |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Jardiance | Empagliflozin | 26 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 25 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 25 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 25 | suppressed |
| Ozempic | Semaglutide | 25 | suppressed |
| Latanoprost | Latanoprost | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 22 |
| Aripiprazole | Aripiprazole | 22 | suppressed |
| Celecoxib | Celecoxib | 22 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Ibuprofen | Ibuprofen | 21 | suppressed |
| Levemir | Insulin Detemir | 21 | suppressed |
| Phenytoin | Phenytoin | 21 | suppressed |
| Finasteride | Finasteride | 20 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 20 | suppressed |
| Mounjaro | Tirzepatide | 20 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 19 | suppressed |
| Insulin Lispro | Insulin Lispro | 19 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 19 | 14 |
| Nystatin | Nystatin | 19 | 11 |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Novolin R | Insulin Regular, Human | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 16 | suppressed |
| Sotalol | Sotalol Hcl | 16 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 15 | suppressed |
| Ketoconazole | Ketoconazole | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Glimepiride | Glimepiride | 14 | suppressed |
| Methimazole | Methimazole | 14 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Cilostazol | Cilostazol | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 13 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 13 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 13 | suppressed |
| Cephalexin | Cephalexin | 12 | 11 |
| Clonidine | Clonidine | 12 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 12 | suppressed |
| Haloperidol | Haloperidol | 12 | suppressed |
| Naproxen | Naproxen | 12 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 12 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 12 | suppressed |
| Premarin | Estrogens, Conjugated | 12 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 12 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 12 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 12 | 11 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 11 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Clarithromycin | Clarithromycin | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Movantik | Naloxegol Oxalate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $129.43 · 5 records | Lilly USA, LLC | AIRSUPRA, Korlym, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error